Episodes
Friday Feb 16, 2024
Heartburn Headache: Cumulative PPI Use and Dementia Risk
Friday Feb 16, 2024
Friday Feb 16, 2024
Omeprazole ranks among the top 10 most prescribed medications in the United States, and many patients take proton pump inhibitors (PPIs) for years. Widespread PPI use persists despite data about potential serious adverse effects. Some worry that PPI use increases the risk of dementia. Are those worries supported by data?
Guest Authors: Molly M. Corder, PharmD, BCPS, BCACP and Ryan S. Ades, PharmD, BCPS
Music by Good Talk
Friday Sep 30, 2022
SAGE Wisdom: Analysis of a Self-Administered Gerocognitive Test
Friday Sep 30, 2022
Friday Sep 30, 2022
Friday Apr 12, 2019
Friday Apr 12, 2019
Intensive blood pressure (BP) control reduces the risk of cardiovascular events and mortality, but the verdict isn't in yet on the benefits of intensive control to prevent the development of dementia. Previous studies have shown an inconsistent relationship between blood pressure control and cognitive decline. SPRINT-MIND, using data from SPRINT, was designed to evaluate the effects of intensive BP control on cognitive outcomes including probable dementia and mild cognitive impairment.
Guest Authors: Michelle Balli, PharmD, BCACP and Amy Robertson, PharmD, BCACP
Music by Good Talk
Friday Apr 08, 2016
Drug Treatment for Agitation in Alzheimer’s Disease: A Conundrum
Friday Apr 08, 2016
Friday Apr 08, 2016
Managing behavioral health in persons withdementia is an enormous and growing problem. Most patients with Alzheimer's disease (AD) have challengingneuropsychiatric symptoms such as agitation. These symptoms are distressing andoften overwhelming for caregivers often resulting in institutionalization andincreased healthcare utilization. Several medications are used off-labelto treat these symptoms including antidepressants, antipsychotics,anticonvulsants, anxiolytics and cholinesterase inhibitors. But manyregulatory bodies, professional associations, and patient advocacy groups havepromoted initiatives to decrease the inappropriate use of medications andencourage the use of alternatives, particularly behavioral interventions. The combination of dextromethorphan hydrobromideand quinidine sulfate (Nuedexta) has been recently studied for the off-labeltreatment of agitation in Alzheimer’s disease. A patient-centered, systematic, andevidence-based approach should be considered when addressing the behavioral and psychological symptoms of dementia.